TXG: 10x Genomics, Inc. Operating Margin

Official company branding of 10xgenomics.com (TXG)

Stable plant utilization and robotics upgrades guarantee the uninterrupted production of cell analysis systems for 10x Genomics, Inc. (TXG). The operating margin trend captures this process, where the -11.50 metric determines this level. Dominance in spatial biology and patent protection provide 10x Genomics, Inc. (TXG) with pricing power, while reagent supplies to oncology and neurobiology centers effectively diversify the company's business risks.

TXG - 10x Genomics Inc Profitability of Operations over the range 07/04/2022 - 11/19/2026

Analytical breakdowns for 10x Genomics, Inc. (TXG)

Analysis of all company metrics:10x Genomics, Inc., TXG
Brand item of 10x

10x Genomics, Inc. (TXG) leadership in spatial biology requires colossal investments in high-tech platforms. The operating margin reflects the efficiency of these activities by comparing operating profit to revenue before financial expenses and taxes. This ratio measures the business's ability to generate profit from its core cycle. Analyzing the marginal income from core operations allows for the identification of trend sustainability. Ignoring risks when interpreting this chart leads to losses.

Competing companies

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability